Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort

Scandinavian Journal of Gastroenterology

Volumn 49, Issue 10, 2014, Pages 1207-1218

  Bauerfeind, Peter ^f   Beglinger, Christoph ^f   Begré, Stefan ^f   Bengoa, José ^f   Binek, Janek ^f   Boller, Daniel ^f   Borovicka, Jan ^f   Braegger, Christian ^f   Burnand, Bernard ^f   Camara, Rafael ^f   Criblez, Dominique ^f   De Saussure, Philippe ^f   Degen, Lukas ^f   Delarive, Joakim ^f   Ehmann, Tobias ^f   Engelmann, Matthias ^f   El Wafa, Ali ^f   Felley, Christian ^f   Frei, Alain ^f   Frei, Remus ^f   Froehlich, Florian ^f   Gallot Lavallée, Suzanne ^f   Geyer, Martin ^f   Girardin, Marc ^f   Goetze, Oliver ^f   Haack, Horst ^f   Hediger, Serge ^f   Hengstler, Peter ^f   Heyland, Klaas ^f   Janiak, Patrick ^f   Juillerat, Pascal ^f   Brondolo, Vera Kessler ^f   Knoblauch, Christoph ^f   Kullak Ublick, Gerd A ^f   Manz, Michael ^f   Marbet, Urs ^f   Meier, Rémy ^f   Meyenberger, Christa ^f   Michetti, Pierre ^f   Mottet, Christian ^f   Müller, Christoph ^f   Müllhaupt, Beat ^f   Nicolet, Thierry ^f   Nydegger, Andreas ^f   Piccoli, Franziska ^f   Pilz, Julia ^f   Rentsch, Ronald ^f   Rey, Jean Pierre ^f   Rogler, Daniela ^f   Sagmeister, Markus ^f   Sauter, Bernhard ^f   Schaub, Niklaus ^f   Schibli, Susanne ^f   Seibold, Frank ^f   Spalinger, Johannes ^f   Stadler, Philippe ^f   Steuerwald, Michael ^f   Straumann, Alex ^f   Sulz, Michael ^f   Thorens, Joël ^f   Vader, John Paul ^f   Vögtlin, Jürg ^f   Von Känel, Roland ^f   Wachter, Gert ^f   Wermuth, Jürg ^f   Wiesel, Paul ^f   more..

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b TRIEMLI HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f NONE

Author keywords

Crohn's disease; Drug switch; Loss of response; Side effects; Tumor necrosis factor; Tumor necrosis factor antagonist; Ulcerative colitis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; INFLIXIMAB; IMMUNOGLOBULIN F(AB) FRAGMENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CROHN DISEASE; DELAYED DIAGNOSIS; DISEASE DURATION; DRUG PREFERENCE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OFF LABEL DRUG USE; PATIENT PREFERENCE; PREGNANCY; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; ADOLESCENT; AGED; ANTAGONISTS AND INHIBITORS; CHILD; COHORT ANALYSIS; COLITIS, ULCERATIVE; DRUG TOLERANCE; INFANT; MIDDLE AGED; PRESCHOOL CHILD; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SWITZERLAND; TIME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; DELAYED DIAGNOSIS; DRUG SUBSTITUTION; DRUG TOLERANCE; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFANT; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RISK FACTORS; SWITZERLAND; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84907257158     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2014.946082     Document Type: Article

References (29)

1. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet 2012; 380:1590-605.
2. Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012;380:1606-19.
3. Peake ST, Bernardo D, Mann ER, Al-Hassi HO, Knight SC, Hart AL.Mechanisms of action of anti-Tumor necrosis factor a agentsinCrohn'sdisease.InflammBowelDis2013;19:1546-55.
4. Chevaux JB, Vavricka SR, Rogler G, Lakatos PL, Schoepfer A, Peyrin-Biroulet L. Mucosal healing with anti-TNF antibodies. Digestion 2012;86:16-22.
5. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-Term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
6. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, van Assche G, et al. Long-Term outcome of treatment with infliximab in 614 patients with Crohn's disease: Results from a single-centre cohort. Gut 2009;337:1029-35.
7. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-Tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial. Gastroenterology 2006;130:323-33.
8. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: A randomized trial. Ann Intern Med 2007; 146:829-38.
9. Lawson MM, Thomas AG, Akobeng AK. Tumor necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;3: CD005112.
10. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-To-severe ulcerative colitis. Gastroenterology 2012;142:257-65.
11. SandbornWJ,FeaganBG, StoinovS,HoniballPJ,RutgeertsP, MasonD,etal.Certolizumabpegol forthetreatment ofCrohn's disease. N Engl J Med 2007;357:2228-38.
12. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen O, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357:239-50.
13. Lichtenstein GR, Thomsen O, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol 2010;8:600-9.
14. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: Systematic review and meta-Analysis. Am J Gastroenterol 2011;106:644-59.
15. Allez M, Vermeire S, Mozziconacci N, Michetti P, Laharie D, Louis E, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010;31:92-101.
16. Van Assche G,Dignass A, Panes J, Beaugerie L, Karagannis J, AllezM,et al.The secondEuropeanevidence-based consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis 2010;4:7-27.
17. Stange EF, Travis SPL, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis 2008;2:1-23.
18. Pittet V, Juillerat P, Mottet C, Felley C, Ballabeni P, Burnand B, et al. Cohort profile: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). Int J Epidemiol 2009;38:922-31.
19. SilverbergMS,Satsangi J,Ahmad T,ArnottID,BernsteinCN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19:5-36.
20. Damas OM, Jahann DA, Reznik R, McCauley JL, Tamariz L, Deshpande AR, et al. Phenotypic manifestations of inflammatory bowel disease differ between Hispanics and non-hispanic whites: Results of a large cohort study. Am J Gastroenterol 2013;108:231-9.
21. van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF therapy: Results from the COIN study. Gut 2014;63:72-9.
22. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 2007; 132:52-65.
23. Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ, et al. Clinical trial: Impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther 2010;32:384-93.
24. Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Schölmerich J, Panes J, et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: An analysis of PRECISE 2 randomized maintenance trial data. Am J Gastroenterol 2010;105:1572-82.
25. Ananthakrishnan AN, Binion DG. Editorial: Improved efficacy of biological maintenance therapy in "early" compared with "late" Crohn's disease: Strike while the iron is hot with anti-TNF agents? Am J Gastroenterol 2010;105:1583-5.
26. Lionetti P, Bronzini F, Salvestrini C, Bascietto C, Canani RB, De Angelis GL, et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003;18:425-31.
27. Azzopardi N, Ellul P. Risk factors for osteoporosis in Crohn's disease: Infliximab, corticosteroids, body mass index, and age of onset. Inflamm Bowel Dis 2013;19: 1173-8.
28. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz R, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
29. Vavricka SR, Bentele N, Scharl M, Rogler G, Zeitz J, Frei P, et al. Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-TNF agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis 2012;18:1523-30.